Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of HNC1058 in Healthy Subjects
NCT05803850Phase 1Completed
- Sponsor
- Guangzhou Henovcom Bioscience Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HNC1058 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Guangzhou Henovcom Bioscience Co., Ltd. Primary endpoint: Number of subjects with adverse events and concomitant medications. Started Mar 2023; status: completed.
02
Drugs
HNC1058
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05803850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803850.